(Q33428423)

English

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Massimo Offidani

object named as

Massimo Offidani

24

0 references

object named as

Albert Oriol

9

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

1

0 references

Gianluca Gaidano

17

object named as

Gianluca Gaidano

2 references

Europe PubMed Central

PubMed publication ID

26 July 2017

ORCID Public Data File 2021

Philippe Moreau

2

object named as

Philippe Moreau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hartmut Goldschmidt

10

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Palumbo

3

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

object named as

Thierry Facon

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

object named as

Heinz Ludwig

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Z Orlowski

27

object named as

Robert Z Orlowski

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Katja Weisel

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alexander Suvorov

13

object named as

Aleksandr Suvorov

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

31

object named as

Wee-Joo Chng

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

object named as

Ludek Pour

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

object named as

Roman Hájek

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

16

object named as

Tomas Pika

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vesselina Goranova-Marinova

19

object named as

Vesselina Goranova-Marinova

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

21

object named as

Leonard Minuk

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

25

object named as

Vania Hungria

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Heidi H Gillenwater

28

object named as

Heidi H Gillenwater

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

29

object named as

Nehal Mohamed

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ievgenii I Karamanesht

23

object named as

Ievgenii Karamanesht

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

object named as

Laura Rosiñol

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Douglas Joshua

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jan Straub

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carla Araujo

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elena Rimashevskaya

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anthony Schwarer

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tamás Masszi

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew Spencer

26

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shibao Feng

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ENDEAVOR Investigators

32

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

3 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

27-38

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A group sequential Holm procedure with multiple primary endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of response endpoints with survival outcomes in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900464-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00464-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33428423&oldid=2126247622"